Dear , In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities. OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi AppTec Research Service Division (RSD), our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Immuno-Oncology

Flow Cytometry Platform for Preclinical Studies and Discovery (1)  Murine TILs composition and corresponding biomarker analysis (2)  Basic panel options for flexible design (3)  Comprehensive immune-profiling in a single panel (4)  TIL baseline of syngeneic models (5)  Intracellular cytokine staining and analysis by flow cytometry (6)  Secreted cytokine analysis by CBA (7)  In vivo or in vitro phosphoflow cytometry analysis on mouse PBMCs ___(pSTAT5 detection) (8) Multiple dimensional analysis of flow cytometry data Read More

Clinical Pathology

Tissue-based Multiplexing Assays for CD47-related Clinical Studies Read More 

Translational Oncology

Ibrutinib-induced Resistant LY-04-0024 Lymphoma PDX Model Read More Radiation Platform for Preclinical Research Flexible and accurate dose rates 1600+ WuXi PDX/CDX/syngeneic models to be selected for study Read More

Targeted Oncology

HER2-related In Vivo Models (1)    HER2-related CDX models 21 HER2-overexpressing cancer cell lines and characterization by in vitro assays BT474, HCC1954 and MDA-MB-468 breast cancer, NCI-N87 gastric cancer, and SK-OV-3 ovarian cancer CDX models, tested with Trastuzumab, T-DM1, and Paclitaxel NCI-N87-luc gastric cancer intracranial implantation model, tested with HER2 inhibitor (2)    HER2-related PDX models HER2 expression level in 12 gastric cancer PDX models IHC and FISH analysis data of HER2-targeted PDX models ST-02-0077, ST-02-0079, ST-02-0103, and ST-02-0074 gastric cancer PDX models, tested with Trastuzumab and T-DM1 BR-05-0434 and BR-05-0452E breast cancer PDX models, tested with Herceptin Read More

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.    Best regards, WuXi AppTec OncoWuXi Team